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We report the synthesis, antibacterial evaluation of a series of thiourea-containing compounds. 1-(3,5-Bis
(trifluoromethyl)phenyl)-3-((S)-(6-methoxyquinolin-4-yl)-((1S,2S,4S,5R)-5-vinylquinuclidin-2-yl)
methyl)thiourea 5, was the most active against a range of Gram-positive and Gram-negative bacteria, and
exhibited bacteriostatic activity against methicillin resistant Staphylococcus aureus (MRSA) comparable to
that of the well-known antibacterial agent vancomycin. Quinoline thiourea 5 was subjected to a detailed
structure–activity relationship study, with 5 and its derivatives evaluated for their bacteriostatic activity
against both Gram-negative and Gram-positive bacteria. A number of structural features important for
the overall activity of quinoline thiourea 5 have been identified. A selection of compounds, including
5, was also evaluated for their in vivo toxicity using the larvae of the Greater wax moth, Galleria mel-
lonella. Compound 5, and a number of derivatives, were found to be non-toxic to the larvae of Galleria
mellonella. A new class of antibiotic can result from the further development of this family of compounds.
 2015 Elsevier Ltd. All rights reserved.The European Centre for Disease Prevention and Control (ECDC)
has estimated that on any given day 1 in 18 hospitalised patients
are suffering with a healthcare-associated infection (HAI).1 The
four most frequently isolated microorganisms from HAIs are
Staphylococcus aureus (S. aureus), Escherichia coli (E. coli), Enterococ-
cus spp. and Pseudomonas aeruginosa (P. aeruginosa).2 Of the
S. aureus derived HAIs, 41% are caused by Methicillin Resistant
S. aureus (MRSA), with 23% of E. coli HAIs resulting from cephalos-
porin-resistant strains.2 In addition, the ECDC has reported that
infections resulting from Gram-negative multidrug-resistant
(MDR) bacteria are on the rise.3,4 In the United States (U.S.) at least
2 million people become infected each year with antibiotic resis-
tant bacteria.5 Of the 2 million infections, approximately 23,000
people die as a direct result.5
This increase in prevalence of antibiotic-resistant bacterial
infections and emergence of new resistant strains are only part
of the problem. The lack of development of new classes of antibac-
terial agents also plays a significant role. Of the antibiotics used
today almost all of them belong to classes discovered before the
1980s, with the exception of the lipopeptides.6 Most of the
advances that have been made since the 1980s have been achievedthrough modifications/improvements to existing antibiotic
classes.6 For example, the fluoroquinolones are more effective
antimicrobial agents than nalidixic acid.7 The global spread of
antibiotic-resistance and the emergence of bacteria resistant to
‘last-resort antibiotics’, coupled with the paucity of new classes
of antibiotics, means that there is an urgent need for antibacterial
research with a focus on the discovery of new antibiotic classes.5,8
We employed a building block approach in our search for new
antibacterial agents, where we wanted to consider compounds
that: (a) bear moieties/blocks that are found in established antimi-
crobial agents or are known to enhance biological activity and (b)
once the blocks are combined, still have the potential to become a
new class of antibiotic. This building block approach aimed to
include structural moieties, or blocks, such as functional groups
bearing fluorine atoms, quinoline bicycles, saturated nitrogen
heterocycles and thioureas, which are all recognised motifs in
antimicrobial agents.9,10
The addition of fluorine is known to enhance drug potency by
improving bioavailability, metabolic stability and protein–ligand
interactions (e.g., Flurithromycin), whilst the quinoline bicycle is
structurally similar to the well-known antibacterial agents, the
quinolones.12,7 Additionally, quinine, a compoundmostwell-known
for its antimalarial properties, has alsobeen shown tobebactericidal
to a number of Gram-positive and Gram-negative bacteria.13–15
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roid activity, however, a vast array of biological activities including
antitubercular, insecticidal, rodenticidal, antiviral, antifungal and
antibacterial activities have also been associated with thiourea-
based compounds.10,11 A recent study on thiourea-based com-
pounds incorporating a hippuric acid moiety was carried out by
Abbas et al.16 The majority of these compounds exhibited broad
spectrum antimicrobial activity with a number of them demon-
strating activity comparable to, and in some cases better than,
ciprofloxacin.16
As such, a number of compounds containing some or all of these
moieties/functional groups were chosen and screened for their
antibacterial activity (Fig. 1).17–19
Each compound was evaluated for their bacteriostatic activity
against the Gram-positive bacterium S. aureus and the Gram-nega-
tive bacterium E. coli. The results of the antibacterial screening
have been summarised in Table 1 and are expressed as the
MIC90, that is, the minimum inhibitory concentration that is
required to inhibit 90% of bacterial growth.
Compounds 5 and 7 were found to be the most active of those
screened (Table 1). As shown in Table 1, compound 5 exhibited
remarkable anti-Staphylococcal activity, with a MIC90 of
<6.25 lM, which was superior to all other compounds screened.
Compound 7 did exhibit higher activity against E. coli than com-
pound 5. However, the almost nanomolar activity of compound 5
against S. aureus prompted us to consider compound 5 in more
detail. As such, compound 5 was subjected to a detailed struc-
ture–activity relationship (SAR) study in order to help understand
its impressive biological activity and to identify the moieties/
functional groups responsible for this activity.
An initial investigation explored the affect the OMe, CF3 and
thiourea groups had on the biological activity of compound 5.
We generated derivatives 5a–c for this purpose (Scheme 1).
Compound 5a was synthesised as described by Oliva et al.20
(Scheme 1). As shown in Scheme 1, the nucleophilic addition of
5a to 3,5-bis(trifluoromethyl)phenyl isothiocyanate generated
compound 5. Alternatively, the reaction of 5a with phenyl isothio-
cyanate gave 5c. The synthesis of 5b was carried out using the
same method as described for 5, however, cinchonidine was used
in place of quinine in the Mitsunobu reaction (Scheme 1).
Each of the compounds, 5 and 5a–c, were evaluated for their
in vitro bacteriostatic activity using the susceptibility assay
described by Kelly et al.21 The three bacteria chosen were,
E. coli, P. aeruginosa and S. aureus, as these are three of the most fre-
quently isolated microorganisms from HAIs.2
The S. aureus and E. coli strains used in this study were clinical
isolates obtained from St. James Hospital, Dublin, Ireland and P.
aeruginosa (10145) was obtained from the American Type Culture
Collection (ATCC). The results are summarised in Table 2. The
results are expressed as the MIC50 and MIC90 range. Vancomycin
hydrochloride (VanHCl) was chosen as the positive control as it
is a well-known antibacterial agent that is often used as a last
resort drug in the treatment of drug-resistant infections, such as
MRSA.9 The vancomycin result has also been included in Table 2.
None of the compounds tested displayed significant activity
against P. aeruginosa (hence these results have been omitted from
Table 2). This lack of activity could be due to the intrinsic resistant
mechanisms associated with P. aeruginosa. For example, the uptake
of molecules by P. aeruginosa is very slow (in comparison to E. coli)
due to its inefficient porins.22 P. aeruginosa can also form a capsule
providing it with an additional physical barrier to prevent the
entry of antibiotics.23,24 Furthermore, P. aeruginosa is well-known
for its ability to grow as a biofilm thus aiding its escape from the
action of antibiotics.25 Perhaps one or a combination of these
mechanisms is responsible for the lack of bacteriostatic activity
observed.As can be seen in Table 2, compound 5 exhibited good activity
against E. coli, resulting in an MIC50 in the range of 2.63–3.95 lM
and 3.95–5.26 lM against S. aureus. Compound 5 also inhibited
E. coli and S. aureus growth by 90% at MIC’s comparable to that
obtained for the reference antibacterial agent, vancomycin
hydrochloride (Table 2).
The results from the susceptibility assays of 5a revealed that it
exhibited little or no activity against E. coli, P. aeruginosa and
S. aureus (Table 2). This is an interesting result as quinine itself has
been shown by others to exhibit bactericidal activity against all
three bacteria.14 However, the small structural differences between
5a and quinine, that is the replacement of the OH with the NH2 and
5a having the opposite stereochemistry to quinine, may be the
reasons behind this lack of activity. Alternatively, the lack of activity
exhibitedby5a could be due to the presence of a third basic nitrogen
group, theNH2, in comparisonwithquinine.When5a is in solution it
has the potential to become protonated,which, in turn,may prevent
it from crossing the lipid membrane of the bacteria. Consequently,
5amay not be able to inhibit bacterial growth.
As can be seen from Table 2, 5b exhibited activity against both
E. coli and S. aureus. The MIC50 values obtained for 5b were slightly
higher than those exhibited by 5, with the MIC90 values obtained
very close to those of 5 (Table 2). Although methoxy groups can
be of importance for binding to target sites through their H-bond-
ing ability,9 these results indicate that for 5, the presence of the
methoxy group is not important for its overall activity.
The effect of removing the two CF3 groups was investigated
using 5c. Compound 5cwas found to be less active than compound
5, displaying a 10- and 14-fold decrease in the MIC50 range against
both S. aureus and E. coli, respectively (Table 2). These results indi-
cate that the CF3 groups appear to be very important in the overall
activity of 5.
As previously discussed, the inclusion of fluorine is known to
enhance drug potency and in addition can increase the lipophilic
character of a compound.12 A useful way of comparing the
lipophilicity of compounds is by calculating their LogP value.9,26
The greater the LogP value, the more lipophilic the molecule. The
cLogP of 5 was found to be approximately 7.33, while that of 5c
was found to have a cLogP of approximately 4.35.27 Therefore
the loss of the CF3 groups, and hence reduction in lipophilicity,
may be impairing the hit compound’s ability to cross the cell mem-
branes and bind to its target site.
Having established the importance of the CF3 and thiourea
groups we then continued our exploration of the structure activity
relationship of compound 5 by maintaining the CF3 substituted
aryl thiourea core and introducing variation to other parts of the
molecule.
In the initial screen (Table 1), compounds 5 and 7were found to
be the compounds that exhibited greatest activity. These com-
pounds share similarities in their structures with both compounds
bearing a 3,5-bis(trifluoromethyl)-phenyl thiourea moiety
attached to a tertiary amine via a two-carbon chain (Fig. 2). To
further explore the importance of these structural similarities com-
pounds 11a, 11b and 12 were designed and synthesised. These
compounds have lower molecular weights than 5 and 7 yet possess
the same connectivity (Fig. 2).
In addition, compounds 13a, 13b, 14 and 15 were also
generated, which allowed us to explore the significance of the basic
tertiary amine group (Scheme 2).
Compounds 11–15 were synthesised using a method similar to
that described by Andrés et al.,28 with modifications (Scheme 2).
As with compounds 5–5c, each of the new derivatives, along
with compound 7, were evaluated for their bacteriostatic activity
against all three bacteria. The results of which have been sum-
marised in Tables 3 and 4. Any inactive compounds have been
excluded from the tables.
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Figure 1. Compounds screened for antibacterial activity.
Table 1
MIC90 values for compounds 1–10
Compound S. aureusa E. colib
MIC90 (lM) MIC90 (lM)
1 >200 >200
2 79.44 ± 22.2 >200
3 >200 >200
4 114.8 ± 25.9 >200
5 <6.25 >200
6 >200 >200
7 23.8 ± 0.1 119.9 ± 13.8
8 189.2 ± 2.2 >200
9 >200 >200
10 124.9 ± 35.6c >200
a S. aureus NCIMB 12702.
b E. coli NCIMB 9485.
c Value given for compound 10 is the MIC82.
N
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(i), (ii), (iii)
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5: R1 = OMe, R2 = CF3, 50%
5b: R1 = H, R2 = CF3, 56%
5c: R1 = OMe, R2 = H, 52%
5a
(iv)
Scheme 1. Synthesis of compound 5 and derivatives 5a–5c. Reactants and
conditions: (i) PPh3, DIAD, 0 C; (ii) DPPA, rt, 12 h and 50 C, 2 h; (iii) PPh3, 50 C,
2 h; (iv) (CF3)2C6H3NCS or PhNCS, rt, 12 h.
Table 2
Antibacterial activity of compounds 5 and 5a-5c as MIC50 and MIC90 ranges
Compound E. coli S. aureus
MIC50 (lM) MIC90 (lM) MIC50 (lM) MIC90 (lM)
VanHCl 1.58–2.10 4.21–6.31 1.58–2.10 4.21–6.31
5 2.63–3.95 7.90–10.52 3.95–5.26 10.52–15.78
5a >309.41 >309.41 >309.41 >309.41
5b 5.54–8.32 8.32–11.08 8.32–11.08 16.62–22.16
5c 40.92–54.56 81.84–109.12 54.56–81.84 163.68–218.24
{Values are the mean of three experiments.}
632 N. Dolan et al. / Bioorg. Med. Chem. Lett. 26 (2016) 630–635Again, none of the compounds, 7 and 11–15, exhibited activity
against the Gram-negative bacterium P. aeruginosa. In fact, 13a
exhibited little or no activity against each of the three bacteria
examined suggesting that the simple 3,5-bis(trifluoromethyl)phe-
nyl thiourea moiety alone is not the source of activity. As shown
in Table 3, 13b only demonstrated activity against E. coli resultingin a MIC50 of 158.20–237.31 lM. Although this is a slight improve-
ment on 13a, the MIC50 achieved by 13b is far removed from that
observed for compound 5 (2.63–3.95 lM). Furthermore, 13b was
unable to inhibit any more than 50% of bacterial growth suggesting
that the simple thiourea structure, and the addition of a two-
carbon chain, is not enough to produce significant antibacterial
activity.
Similar to 13a, compound 11a demonstrated little or no bacte-
riostatic activity against all three bacteria. Compound 11b on the
other hand resulted in an MIC50 of 96.87–129.16 lM against both
E. coli and S. aureus. Furthermore, 11b had the ability to inhibit
up to 90% of bacterial growth, although a higher concentration
was required to do so (Table 4). These results indicate that
although the addition of the two-carbon chain bound to a simple
dimethyl tertiary amine did not improve bacteriostatic activity
(compound 11a), the addition of a slightly more hydrophobic and
slightly larger tertiary amine (diethylamine) was beneficial for
activity. What is more, in comparison to 13b, which was inactive
against S. aureus, the addition of the –NEt2 group, 11b, resulted
in a compound that can inhibit up to 80% of S. aureus growth at a
concentration range of 129.16–193.74 lM (see Supporting
information).
As shown in Table 3 and 12 (containing a quinuclidine hetero-
cycle, as found in compound 5) was more active than 13b and
11b against both E. coli and S. aureus. Furthermore, 12 can inhibit
the growth of both E. coli and S. aureus by 50%, at the same concen-
tration, with an increase in concentration resulting in an increase
in bacteriostatic activity (Tables 3 and 4).
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Scheme 2. Synthesis of compounds 11–15. Reactants and conditions: (i) rt,
overnight.
Table 4
Anti-MRSA activity of compounds 5, 5b, 7, 11b and 12 as MIC50 and MIC90 ranges
Compound MRSA MRSA
MIC50 (lM) MIC90 (lM)
5 11.44a 17.74a
5b 10.81a 18.11a
7 21.54a 32.25a
11b 13.47a 23.52a
12 20.73a 31.44a
Vancomycin — 1.35b
a Clinical isolate, {values are the mean of four experiments}.
b Published literature data.30,31
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5.63, which is a slight increase in cLogP compared to that of 11b
(5.09 ± 0.54).27 Therefore, perhaps this increase in lipophilicity
improves activity although the change in cLogP is marginal. Addi-
tionally, these results suggest that the more sterically bulky quin-
uclidine ring is favourable for activity.
Comparing results for 13b with 12 suggest that a basic tertiary
nitrogen, in combination with steric bulk/lipophilicity, has a bene-
ficial effect on activity. To further investigate this theory com-
pounds 14 and 15 were synthesised, which do not have a basic
nitrogen but retained some steric and lipophilic properties
(Scheme 2). Both 14 and 15 were evaluated for their bacteriostatic
activity. Compound 14 exhibited activity against both E. coli and S.
aureus resulting in MIC50 ranges of 101.33–135.10 and 135.10–
202.65 lM, respectively (Table 3). Compound 15 on the other hand
only exhibited activity against E. coli, however, the MIC50 obtained
was lower than that of 14 (Table 3). Additionally, an increase in 15
concentration resulted in an increase in percentage of growth inhi-
bition, whereas 14 did not inhibit greater than 50% of bacterial
growth (Tables 3 and 4). In terms of structure, both 14 and 15 con-
tain a lipophilic six-membered carbon ring with the difference
being that, in 15 it is planar and aromatic whereas for 14 it is
non-planar and of greater steric bulk (Charton values: Ph = 0.57
and cyclohexyl = 0.8729). Both compounds, 14 and 15, were signif-
icantly less active than 12 and 5, suggesting that the presence of a
basic nitrogen is of paramount importance.Table 3
Antibacterial activity of compounds 5, 7 and 11–15 as MIC50 and MIC90 ranges
Compound E. coli
MIC50 (lM) MIC90 (lM)
VanHCl 1.58–2.10 4.21–6.31
5 2.63–3.95 7.90–10.52
7 60.51–90.77 121.02–181
11b 96.87–129.16 193.74–258
12 42.89–57.19 85.78–114.3
13b 158.20–237.30 >316.41
14 101.33–135.10 >270.20
15 51.50–68.67 206.02–274
{Values are the mean of three experiments.}As a result of this synthetic and evaluation study, considerable
information was attained relating compound structure to biologi-
cal activity and the outcomes from this SAR exercise are sum-
marised in Figure 3.
The antibacterial activity of several compounds, particularly
compounds 5 and 5b, was quite promising and as a result addi-
tional testing against the resistant strain MRSA was performed.
The anti-MRSA results for compounds 5, 5b, 7, 11b and 12, the
top five compounds against S. aureus, are shown in Table 4.
All five compounds displayed significant activity levels against
MRSA, with MIC50 and MIC90 values in the low lM range.
Compounds 5 and 5b were the most impressive, exhibiting low
MIC90 values of 17.74 and 18.11 lM respectively. This compares
favourably with the reported anti MRSA MIC90 value for van-
comycin of 1.35 lM or 2 mg/L (vancomycin is the antibacterial
agent commonly used in the treatment of MRSA infection).30,31
As such, the quinoline thiourea structure, as found in compound
5, has significant potential as a new antibacterial agent class.
In developing new antibacterial agents it is important to deter-
mine, as early as possible, if the antibacterial properties are simply
due to the compounds being toxic in nature (i.e., not selective for
bacteria). To investigate this possibility, in vivo toxicity studies
were carried out, as described by Rowan et al.32 using the larvae
of the Greater wax moth, Galleria melonella (G. melonella),
(Fig. S25 in Supplementary information).
The similarities between the innate immune system of insects
and mammals have led to the use of insects as in vivo models for
investigating the virulence of many human pathogens including
Gram-negative bacteria, Gram-positive bacteria, and fungi.33–35
The larvae of the Greater wax moth, G. mellonella, have been used
as an in vivo model in a number of studies to investigate the viru-
lence of human pathogens.34,35 G. mellonella larvae have also been
used to evaluate both the therapeutic effect of current and novel
antimicrobial agents and the in vivo tolerance of novel antimicro-
bial agents.36,37 An investigation into the toxicity of copper(II) and
silver(I) complexes by McCann et al.38 has demonstrated that the
level of toxicity exhibited by the test compounds in G. mellonella
was similar to that observed in Swiss mice.S. aureus
MIC50 (lM) MIC90 (lM)
1.58–2.10 4.21–6.31
3.95–5.26 10.52–15.78
.54 60.51–90.77 90.77–121.02
.32 96.87–129.16 193.74–258.32
8 42.89–57.19 85.78–114.38
>316.41 >316.41
135.10–202.65 >270.20
.69 >274.69 >274.69
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N
F3C CF3
O
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Loss of the–OMe group
reduced potency
but it may not be essential
for over all activity
The presence of a stericaly bulky
group was favourable for activity
A two-carbon chain linking a
–NEt2 group to the thiourea moiety
was beneficial for activity
Loss of the–CF3 groups
severely reduced activity
Structurally simple
3,5-bis(trifluoromethyl)-
phenyl thiourea derivatives
show little or no activity
Loss of the quinoline
group greatly
reduced activity
The quinine-derived
amine moiety alone
was inactive
Figure 3. SAR study summary of quinoline thiourea 5.
634 N. Dolan et al. / Bioorg. Med. Chem. Lett. 26 (2016) 630–635Compound 5, and a selection of derivatives that exhibited
antibacterial activity (5b, 5c, 11b, 12 and 15) were chosen for the
evaluation of their toxicity. Almost all compounds tested displayed
a 100% survival rate of G. mellonella larvae at a range of concentra-
tions. Compounds 5b, 5c, 11b, 12 and 15, at a concentration of
1 lg/mL, all displayed a 100% survival rate after 72 h. Increasing
the administration dose to 10, 50 and 100 lg/mL did not appear
to affect the G. mellonella larvae. A 100% survival rate was observed,
at each of these concentrations, for every compound tested, includ-
ing compound 5. The in vivo toxicity of our most active compound,
compound 5, was also evaluated at the higher concentration of
1000 lg/mL, and once more was found to be non-toxic. A table
of results showing survival rates (100% in almost all cases) at 24,
48 and 72 h, and at a range of concentrations, can be found in
Supplementary information.
The G. mellonella larvae were also monitored for their develop-
ment, that is, whether or not the larvae proceeded along their nor-
mal developmental pathway to form pupae. It was found that after
seven days, at each test compound concentration, the number of
the G. mellonella larvae that had pupated was similar to that
observed for the untreated G. mellonella (P60%). These results
indicate that not only were the compounds non-toxic to the larvae
of the Greater wax moth but they also did not appear to interfere
with larval development.
In conclusion, we have described the identification of a new
quinoline thioureaantimicrobial agent, compound5. All compounds
were evaluated for their bacteriostatic, andnot bactericidal, activity.
The antibacterial activity of the quinoline thiourea 5was discovered
whenscreening selected compoundsagainstE. coli,P. aeruginosa and
S. aureus.The compelling activity of compound5 against E. coli and S.
aureus, activity comparable to vancomycin hydrochloride, necessi-
tated an exploration of its structure activity relationship and addi-
tional testing against the resistant strain MRSA. Both compounds 5
and 5b displayed significant anti MRSA activity, again comparable
to vancomycin. Additionally, and importantly, compound 5, and a
number of derivatives, were also found to be non-toxic to
G. mellonella larvae at concentrations of up to 1000 lg/mL (in the
case of compound 5). Overall, these results suggest that the quino-
line thiourea structure, as found in compound 5, has potential as a
new class of non-toxic, anti MRSA agent.
Acknowledgments
This research was funded through the Irish Higher Education
Authority Programme for Research in Third Level Institutions—Cycle 4 and co-funded by the European Union under the European
Regional Development Fund.
Supplementary data
Supplementary data (synthetic procedures, compound charac-
terisation data, NMR spectra and biological assay protocols/results)
associated with this article can be found, in the online version, at
http://dx.doi.org/10.1016/j.bmcl.2015.11.058.
References and notes
1. ECDC Surveillance Report 2013, Summary. Point Prevalence Survey of
Healthcare-Associated Infections and Antimicrobial Use in European
Hospitals 2011–2012.
2. ECDC Surveillance Report 2013. Suetens, C.; Hopkins, S.; Kolman, J.; Högberg, L.
D., European Centre for Disease Prevention and Control. Point Prevalence
Survey of Healthcare-Associated Infections and Antimicrobial Use in European
Acute Care Hospitals 2011–2012.
3. ECDC Annual Epidemiological Report 2013. Reporting on 2011 Surveillance
Data and 2012 Epidemic Intelligence Data; Stockholm: ECDC.
4. EARS-Net Report for Quater 1 2013.
5. CDC Antibiotic Resistance Threats in the United States, 2013.
6. Livermore, D. M. J. Antimicrob. Chemother. 2011, 66, 1941.
7. Antriole, V. T. The Quinolones, 3rd ed.; Academic Press: San Diego, California,
2000.
8. ECDC/EMEA Joint Technical Report. The Bacterial Challenge: Time to React. A
Call to Narrow the Gap between Multidrug-Resistant Bacteria in the EU and the
Development of New Antibacterial Agents, 2009.
9. Patrick, G. L. An Introduction to Medicinal Chemistry, 3rd ed.; Oxford University
Press: New York, 2005.
10. Schroeder, D. C. Chem. Rev. 1955, 55, 181.
11. Mitchell, S. C.; Steventon, G. B. Sulfur Rep. 1994, 16, 117.
12. Purser, S.; Moore, P. R.; Swallow, S.; Gouverneur, V. Chem. Soc. Rev. 2008, 37,
320.
13. Kalotka-Kreglewska, M. Cent. Eur. J. Immunol. 2011, 36, 100.
14. Kharal Saleem, A.; Hussain, Q.; Ali, S.; Fakhuruddin J. Pak. Med. Assoc. 2009, 59,
208.
15. Wolf, R.; Baroni, A.; Greco, R.; Donnarumma, G.; Ruocco, E.; Tufano, M. A.;
Ruocco, V. Ann. Clin. Microbiol. Antimicrob. 2002, 1, 5.
16. Abbas, S. Y.; El-Sharief, M. A. M. S.; Basyouni, W. M.; Fakhr, I. M. I.; El-Gammal,
E. W. Eur. J. Med. Chem. 2013, 64, 111.
17. Gavin, D. P.; Stephens, J. C. ARKIVOC 2011, 407.
18. Okino, T.; Hoashi, Y.; Takemoto, Y. J. Am. Chem. Soc. 2003, 125, 12672.
19. Gavin, D. P.; Stephens, J. C. ARKIVOC 2013, 76.
20. Oliva, C. G.; Silva, A. M. S.; Resende, D. I. S. P.; Paz, F. A. A.; Cavaleiro, J. A. S. Eur.
J. Org. Chem. 2010, 3449.
21. Kelly, J.; Rowan, R.; McCann, M.; Kavanagh, K. Med. Mycol. 2009, 47, 697.
22. Meyer, A. L. Curr. Opin. Pharmacol. 2005, 5, 490.
23. Nikaido, H. Drug Resist. Updates 1998, 1, 93.
24. Govan, J. R.; Deretic, V. Microbiol. Rev. 1996, 60, 539.
25. Hoiby, N.; Johansen, H. K.; Moser, C.; Song, Z.; Ciofu, O.; Kharazmi, A. Microbes
Infect. 2001, 3, 23.
26. Lipinski, C. A.; Lombardo, F.; Dominy, B. W.; Feeney, P. J. Adv. Drug Delivery Rev.
1997, 23, 3.
N. Dolan et al. / Bioorg. Med. Chem. Lett. 26 (2016) 630–635 63527. All cLogP values were calculated using ACD/Labs ChemSketch 12.0.
28. Andres, J. M.; Manzano, R.; Pedrosa, R. Chem. Eur. J. 2008, 14, 5116.
29. Charton, M. J. Am. Chem. Soc. 1975, 97, 1552.
30. Appleman, M. D.; Citron, D. M. Diagn. Microbiol. Infect. Dis. 2010, 66, 441.
31. Sancak, B.; Yagci, S.; Mirza, H. C.; Hascelik, G. J. Antimicrob. Chemother. 2013, 68,
2689.
32. Rowan, R.; Moran, C.; McCann, M.; Kavanagh, K. Biometals 2009, 22, 461.
33. Hamamoto, H.; Kurokawa, K.; Kaito, C.; Kamura, K.; Razanajatovo, I. M.;
Kusuhara, H.; Santa, T.; Sekimizu, K. Antimicrob. Agents Chemother. 2004, 48,
774.34. Brennan, M.; Thomas, D. Y.; Whiteway, M.; Kavanagh, K. FEMS Immunol. Med.
Microbiol. 2002, 34, 153.
35. Peleg, A. Y.; Monga, D.; Pillai, S.; Mylonakis, E.; Moellering, R. C., Jr.; Eliopoulos,
G. M. J. Infect. Dis. 2009, 199, 532.
36. Desbois, A. P.; Coote, P. J. J. Antimicrob. Chemother. 2011, 66, 1785.
37. Kellett, A.; O’Connor, M.; McCann, M.; Howe, O.; Casey, A.; McCarron, P.;
Kavanagh, K.; McNamara, M.; Kennedy, S.; May, D. D.; Skell, P. S.; O’Shea, D.;
Devereux, M. MedChemComm 2011, 2, 579.
38. McCann, M.; Santos, A. L. S.; da Silva, B. A.; Romanos, M. T. V.; Pyrrho, A. S.;
Devereux, M.; Kavanagh, K.; Fichtner, I.; Kellett, A. Toxicol. Res. 2012, 1, 47.
